Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR!

To ensure the community can capitalize on this, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73, CD39, A2A and A2B focused therapeutics.

Join this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage, utilize novel technologies and approaches through translation to clinical development to improve patient selection, and discover new ways of finding mono and combo therapy approaches to increase potency and safety.

Top Speakers includes:

• Alex Gaither, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates
• Changyun Hu, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more
• Joanne Lager, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure

& 15+ more expert speakers!

Download your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5

Interested in speaking? Contact info@hansonwade.com

Interested in sponsoring? Contact sponsor@hansonwade.com